In view of the common coactivation of HDACs and other cancer‐promoting pathways in GBC, such as PI3K‐AKT and Ras signaling, we aimed to determine whether combined inhibition of these pathways with HDACs has synergistic antitumour effects against GBC patients. This evidence concerns the gene AKT1 and cancer.